STOCKHOLM – August 31st, 2017 – ContextVision, a medical technology company specializing in image analysis and artificial intelligence, received a US patent approval for a new technology based on artificial intelligence. The technology serves to optimize image quality within ultrasound as well as other medical modalities i.e. MRI, X-ray and CT. The patent was filed in September 2014, and is titled “-Methods and systems for automatic control of subjective image quality in imaging of objects”.
The artificial intelligence technology, developed within the company, combines the subjective perception of an image into algorithms used to evaluate and enhance image quality automatically without direct involvement of a clinical expert.
“This new technology provides us with a new platform for product development which we call the “Virtual Expert”. The aim is to automatize image quality adjustments,” says Anita Tollstadius, CEO, ContextVision.
Image quality is crucial for image-based diagnosis, and clinicians and sonographers often spend a significant amount of time optimizing an image. This new technology offers a completely new approach to automatically generate an optimal image for each patient. The ability to automatically adjust image quality allows increased improvement in the diagnostic value of medical imaging.
“We have been experts in image quality and image enhancement software for more than 30 years and this patent approval demonstrates our capacity to combine artificial intelligence with our long experience within image quality,” says Tollstadius.
For further information, please contact ContextVision’s CEO, Anita Tollstadius, at +46 70 337 30 26.
ContextVision is a medical technology company specializing in image analysis and artificial intelligence. Its cutting-edge technology helps doctors accurately interpret medical images, a crucial foundation for better diagnosis and treatment. As an industry pioneer for more than 30 years, ContextVision is taking a leading position within deep learning, the latest artificial intelligence technology. ContextVision is currently investing significantly in the field to expand its product portfolio. The present product portfolio includes state-of-the-art image enhancement software for 2D/3D/4D ultrasound, MRI, X-ray and mammography which is used by leading equipment manufacturers worldwide. ContextVision is based in Sweden and listed on the Oslo Stock Exchange under the ticker COV. For more information, please visit http://www.contextvision.com.